Show simple item record

dc.contributor.authorRand, Kim
dc.contributor.authorRamos-Goñi, Juan Manuel
dc.contributor.authorAkmaz, Bülent
dc.contributor.authorSolé-Feu, Laia
dc.contributor.authorArmario Hita, José Carlos 
dc.contributor.otherCirugíaes_ES
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2024-06-27T14:55:19Z
dc.date.available2024-06-27T14:55:19Z
dc.date.issued2024
dc.identifier.issn2190-9172
dc.identifier.issn2193-8210
dc.identifier.urihttp://hdl.handle.net/10498/32805
dc.description.abstractAuthors would like to correct the Error in Fig. 1, which should illustrate that the study arms were compared in the study. As reflected in the text, these are the Q2W arm from the SOLO-CONTINUE study and the Q4W arms from the ADvocate trial. However, the gold border for the ADvocate trials is erroneously placed around the Q2W arms. The revised version of Fig. 1 is updated here. The revised version of Table 1 isupdated here. (Table presented.) SOLO-CONTINUE and corresponding ADvocate aggregate data Variable SOLO-CONTINUE Dupilumab QW/Q2W ADvocates 1 & 2 N (%) 169 (100%) 101 (100%) Race Asian, n(%) 31 (18.3%) 14 (13.9%) Other, n(%) 14 (8.3%) 12 (11.9%) Baseline scores (maintenance baseline, week 16 of treatment) EASI-75, n (%) 162 (95.9%) 101 (100%) IGA, mean (SD) 1.15 (0.61) 1.2 (0.85) IGA 0/1, n (%) 129 (76.3%) 63 (62.4%) DLQI, mean (SD) 3.4 (4.21) 3.5 (3.47) POEM, mean (SD) 6.4 (5.3) 7.7 (5.3) End-of-study scores (week 52 of treatment) IGA 0/1, n (%) 68 (40.2%) 56 (55.4%) EASI-75, n (%) 116 (68.6%) 69 (68.3%) Overall AE, n (%) 118 (69.8%) 74 (73.3%) Bold italics for variables used in propensity score weighting SD: Standard Deviation; QW/Q2W: weekly or bi-weekly administration; EASI: Eczema Area and Severity Index; IGA: Investigator Global Assessment; DLQI: Dermatology Life Quality Index; POEM: Patient Oriented Eczema Measure; BSA: Body Surface Area; IGA 0/1: IGA score of 0 or 1, clear/almost clear skin; EASI-75: 75% improvement in EASI score from baseline; AE: Adverse Events Affiliation of authors Kim Rand and Juan Manuel Ramos-Gon updated from ‘Health B.V’ to ‘Maths in Health B.V’. (Figure presented.) ADvocate and SOLO-CONTINUE trial designs. The arms used in this study are outlined in gold The original article has been corrected.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherAdises_ES
dc.rightsAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.sourceDermatology and Therapy (Heidelb) (2024) 14:183–185es_ES
dc.titleCorrection to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis (Dermatology and Therapy, (2024), 14, 1, (169-182), 10.1007/s13555-023-01058-z)es_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1007/S13555-023-01076-X
dc.type.hasVersionVoRes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial 4.0 Internacional
This work is under a Creative Commons License Atribución-NoComercial 4.0 Internacional